Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 >= 1% status confers therapeutic sensitivity to Cisplatin, Nivolumab, Pemetrexed in patients with Non-Small Cell Lung Cancer.
The Republic of Ireland's Health Service Executive (HSE) has approved nivolumab in combination with cisplatin and pemetrexed for reimbursement as a treatment option for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). The regimen further states that this combination is available in NCIS (00849.5).
This statement is based on a regulatory approval from the Health Service Executive:
In combination with nivolumab for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1% (3 cycles only). This combination is available in NCIS (00849.5)